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ABSTRACT 
Primary cutaneous diffuse large B-cell lymphoma, leg type (PCDLBCL-LT) and primary 
cutaneous follicle center lymphoma (PCFCL) are cutaneous B-cell lymphomas (CBCL) with different 
clinical characteristics and behavior. PCDLBCL-LT is the most aggressive CBCL with a relatively poor 
prognosis. In nodal diffuse large B-cell lymphoma (DLBCL), rearrangements of the MYC gene, 
especially in combination with a second hit in BCL2 and/or BCL6, and double protein expression of 
MYC and BCL2 (DE) are adverse prognostic factors. As the clinical significance of these factors in 
CBCL is largely unknown, we studied the frequency and prognostic value of MYC rearrangements 
and DE in a cohort of 44 patients with PCDLBCL-LT and 17 patients with PCFCL. Compared with nodal 
DLBCL (9-14%), the PCDLBCL-LT patients had a high incidence of MYC rearrangements (32%), but 
only two patients (4%) had a second hit, both with BCL6. PCDLBCL-LT patients with a MYC 
rearrangement showed an inferior disease-specific survival (Log-rank,p=0.036) and disease-free 
survival (Log-rank,p=0.028), but no significant adverse effect on overall survival (Log-rank,p=0.157) 
at 5 years compared with patients without a MYC rearrangement. DE, present in 65% of the 
PCDLBCL-LT patients, was not associated with reduced survival. In the PCFCL group, MYC 
rearrangements and DE were not detected. In conclusion, this study identifies a high incidence of 
MYC rearrangements in PCDLBCL-LT compared with nodal DLBCL and further shows that a MYC 
rearrangement is an inferior prognostic marker in these patients. Therefore, our data suggest that it 
is useful to perform MYC-FISH in all newly diagnosed PCDLBCL-LT patients.  
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INTRODUCTION 
Primary cutaneous diffuse large B-cell lymphoma, leg type (PCDLBCL-LT) and primary 
cutaneous follicle center lymphoma (PCFCL) are both cutaneous B-cell lymphomas (CBCL) with a 
large cell morphology. Whereas PCFCL patients have an excellent prognosis with a 5-year disease-
specific survival (DSS) of over 95%, PCDLBCL-LT is a more aggressive type of CBCL with a 5-year DSS 
of ~55%.(1) So far, the only adverse prognostic factors that have been identified are presentation 
with multiple skin lesions, loss of 9p.21 (CDKN2A/B), and hotspot mutations in MYD88 L265P.(2-4) 
In 9 to 14% of nodal diffuse large B-cell lymphomas (DLBCLs), rearrangements of the MYC 
gene are present, which is associated with a poor prognosis.(5-8) In over half of the cases, MYC 
rearrangements occur in combination with a second hit in the BCL2 and/or BCL6 genes and these 
patients demonstrate an even worse outcome with a median overall survival (OS) reported between 
0.2 and 1.5 years.(5, 8-12) In the 2017 revision of the WHO c double hit 
lymphomas  (or triple hit lymphomas ) are classified as a separate disease entity with a very 
aggressive behavior.(13) In addition, 19 to 34% of the DLBCL patients have double protein 
expression of MYC and BCL2 (DE), but lack genetic rearrangements in these genes, demonstrating an 
intermediate survival between DLBCL with single or no expression of MYC and BCL2, and DLBCL with 
double or triple hits.(14-16) Regarding the cell-of-origin, single MYC rearrangements and double hits 
with BCL6 show a rather equal distribution between the germinal center B-cell (GCB) and the 
activated B-cell (ABC) subtypes, whereas double hits with BCL2 and triple hits are characteristic for 
GCB-DLBCL and do not seem to occur in ABC-DLBCL.(17) In addition, DE is more common in the ABC 
subtype.(16) 
Gene-expression profiling of CBCL showed that PCDLBCL-LT is similar to the ABC-subtype and 
PCFCL to the GCB-subtype of nodal DLBCL.(18) Correspondingly, the vast majority of PCDLBCL-LT 
patients expresses MUM1 and BCL2, approximately two-third is positive for BCL6, while CD10 
expression is usually lacking.(19, 20) Molecular studies identified highly recurrent mutations in genes 
that are predominantly involved in -signalling pathway, such as MYD88, PIM1, and 
CD79B.(21-23) The presence of MYC rearrangements and MYC protein expression has only been 
studied in a small number of patients with CBCL with very diverse results and the relation between 
MYC rearrangements and survival is unknown.(22, 24-26) 
Considering the small number of studied CBCL patients and the clinical relevance in nodal 
DLBCL, the purpose of this study was to evaluate the frequency and prognostic significance of MYC 
rearrangements, either alone or in combination with BCL2 and/or BCL6 rearrangements, and of DE in 
a relatively large cohort of PCDLBCL-LT and PCFCL patients.  
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MATERIALS AND METHODS 
All patients with PCDLBCL-LT, consecutively diagnosed in the Leiden University Medical 
Center (LUMC), Leiden, The Netherlands between 2000 and 2017 were selected from the Cutaneous 
Lymphoma database (n=47). In addition, a random selection of patients with PCFCL, diagnosed in the 
same period, were included (n=20). In all cases, diagnoses was confirmed by a panel of 
dermatologists and pathologist during one of the regular meetings of the Dutch Cutaneous 
Lymphoma Group, according to the criteria of the WHO-EORTC classification.(1) In all patients, the 
presence of extracutaneous disease at time of diagnosis was excluded by standard staging 
procedures, consisting of a combination of physical examination, complete blood count and 
chemistry, chest radiography, computerized tomography of thorax and abdomen, and bone marrow 
cytology and/or histology. Clinical presentation and follow-up data were collected from the registry 
of the Dutch Cutaneous Lymphoma Group and/or from the medical records. Patients were excluded 
in case of insufficient tissue samples for molecular analysis (n=3 for PCDLBCL-LT; n=3 for PCFCL). The 
study was performed in accordance with the Code Proper Secondary Use of Human Tissue 
established by the Dutch Federation of Medical Sciences, as approved by the medical ethics 
committee of the LUMC (B16.048). 
 
Immunohistochemistry 
The pretreatment formalin-fixed and paraffin-embedded skin biopsies from the included 
patients were collected from the archives of the Department of Pathology of the LUMC. Sections of 
3µm were immunostained with antibodies against MYC (clone Y69, diluted 1:100; ABCAM), BCL2 
(clone 124, diluted 1:80; Dako, Glostrup, Denmark), BCL6 (clone PG-B6p, diluted 1:100; Invitrogen), 
CD20 (clone L26, diluted 1:800; Dako) and/or CD79A (clone JCD117, diluted 1:100; Dako), CD10 
(clone 56C6, diluted 1:20; Dako), MUM1 (clone MUM1p, diluted 1:100; Dako), and IgM (polyclonal, 
diluted 1:500; Dako) using the Dako Autostainer Link 48 (Dako) according to standard staining 
procedures. Immunohistochemical expression by the tumor cells was estimated by the authors 
A.M.R.S., P.M.J., and R.W., until consensus was reached. MYC expression was scored with the 
standard cutoff value of 40%.(27) The other immunohistochemical markers were scored with a 
cutoff value of 30% for CD10, BCL6, and MUM1, and 50% for BCL2 and IgM. DE was defined as 
combined expression of MYC and BCL2. 
 
Fluorescence in situ hybridization 
Fluorescence in situ hybridization (FISH) was performed with Vysis Dual Color Break Apart 
Rearrangement Probes from Abbott using the Dako Histology FISH Accessory Kit, according to 
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standard procedures. All cases were manually scored by A.M.R.S and J.K.K. and considered 
rearranged with a split of the signals in 10% of the tumor cells. In case of a MYC rearrangement, 
additional FISH for BCL2 and BCL6 was performed with Vysis Dual Color Break Apart Rearrangement 
Probes from Abbott and the Dako Histology FISH Accessory Kit, according to the same procedures. In 
the PCFCL group, FISH for BCL2 was also performed on cases with BCL2 expression. 
 
Statistical analysis 
Statistical analysis was performed using IBM SPSS Statistics 23. Survival was defined as the 
date of diagnosis until the date of death by any cause (OS) or the date of death from lymphoma 
(DSS). Disease-free survival (DFS) was calculated from the date of diagnosis until the time of relapse 
or progression of disease or death from lymphoma. Patients without an event at the last date of 
follow-up were censored. For the DSS and DFS, patients who died from an unrelated cause were also 
censored. Comparison between the subgroups based on MYC rearrangements and DE occurred with 
the Mann-Whitney U test for continuous data and the 2 for categorical data. Survival curves were 
plotted using the Kaplan-Meier method and compared with the Log-rank test. Corresponding hazard 
ratios (HR) and their 95% confidence intervals (95% CI) were calculated in a Cox proportional-
hazards model. A p-value of <0.05 was considered statistically significant. 
 
RESULTS 
In total, 44 patients with PCDLBCL-LT were included: 25 (57%) females and 19 (43%) males. 
The patient characteristics and an overview of the results are presented in Table 1 and Figure 1. The 
median age at diagnosis was 78 (range, 49 to 92) years. At presentation, disease was located on the 
legs in 35 (80%) patients and in sites other than the legs in 9 (20%) patients. Extent of disease was 
solitary in 11 (25%) patients, localized (multiple lesions in one body region) in 28 (64%) patients, and 
generalized (multiple lesions in more than one body region) in 5 (11%) patients. Histologically, the 
skin lesions showed a diffuse infiltrate of centroblasts and immunoblasts throughout the entire 
dermis, in some cases extending into the subcutaneous tissue (Figure 2). These B-cells showed 
uniform and strong expression of BCL2 in 42 (95%) cases, MUM1 in 36 (84%) cases and IgM in 42 
(95%) cases, while expression of CD10 was seen in 7 (16%) patients, with a very weak expression in 3 
of them. In addition, BCL6 was positive in 27 (61%) patients. 
The PCFCL group consisted of 17 patients, including 5 (29%) females and 12 (71%) males. 
Patients were diagnosed at a median age of 58 (range, 46 to 69) years. In all patients, lesions were 
located on the head or trunk, and in one patient also one leg was involved. Histologically, the growth 
pattern was follicular in 2 (12%) cases, follicular/diffuse in 4 (24%) cases, and diffuse in 11 (65%) 
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cases. The tumor cells were positive for BCL6 in all cases and for CD10 in 14 (82%) cases, while none 
of the cases expressed MUM1. BCL2 was expressed in 2 (12%) cases, of which one harbored a BCL2 
rearrangement. Two other cases (12%) had membranous staining of IgM. 
 
Follow-up and survival 
The PCDLBCL-LT patients were initially treated with immunochemotherapy (CHOP with 
rituximab) in 16 (36%) cases, chemotherapy (CHOP) in 6 (14%) cases, local radiotherapy in 20 (45%) 
cases, and surgery alone in 1 (2%) case. In one other patient (2%), no treatment was given due to 
spontaneous remission of a solitary lesion. After initial therapy, 41 (93%) patients reached complete 
remission. Twenty-three (52%) patients developed cutaneous relapses during follow-up and 15 
patients (34%) had relapses at extracutaneous sites. The median disease-free period was 12 (range, 
0 to 105) months. After a median duration of follow-up of 41 (range, 4 to 125) months, 15 (34%) 
patients were still alive with or without ongoing disease, 20 (45%) patients died from lymphoma and 
9 (20%) patients died from an unrelated cause. In our cohort of PCDLBCL-LT patients, OS was 46%, 
DSS was 52%, and DFS was 39% at 5 years. 
In the PCFCL group, all cases reached complete remission after initial treatment. The median 
duration of follow-up was 63 (range, 4 to 224) months during which skin relapses occurred in 11 
(65%) patients, and 2 (12%) patients had extracutaneous dissemination (in both cases to lymph 
nodes). After follow-up, all patients were still alive with or without ongoing disease, resulting in a 5-
year OS and DSS of 100%. 
 
MYC rearrangements and DE 
In total, 14 (32%) PCDLBCL-LT cases showed a rearrangement of the MYC gene, with a 
double hit of BCL6 in 2 of them. No double hits with BCL2 were present. Interestingly, CD10 
expression was only observed in patients with wild type MYC. DE was seen in 28 of 43 (65%) 
patients, including 12 of the 14 (86%) cases with a MYC rearrangement and one of the 2 cases with a 
double hit (Figure 2). The other double hit case was negative for MYC with expression in ~30% of the 
tumor cells. As 95% of the patients with PCDLBCL-LT expressed BCL2, the frequency of DE (65%) was 
similar to expression of MYC alone (29/43; 67%).  
All 17 cases of PCFCL were MYC-wild type and none of the cases expressed MYC. In 15 (88%) 
cases, MYC was only expressed by <10% of the tumor cells, and the remaining 2 cases expressed 
MYC in ~20% of the tumor cells. For comparison, in the PCDLBCL-LT group, only 4 of 43 (9%) cases 
expressed MYC in <10% of the tumor cells. As MYC was always negative, none of the PCFCL cases 
were double expressors.  
7 
 
 
Prognostic factors 
In PCDLBCL-LT patients, the presence of a MYC rearrangement was associated with a 
statistically significantly reduced 5-year DSS (Log-rank, p=0.036; HR, 2.67; 95% CI, 1.03-6.96; Figure 
3A) and DFS (Log-rank, p=0.028; HR, 2.47; 95% CI, 1.05-5.78; Figure 3B), but not with a reduced OS 
(Log-rank, p=0.157; HR, 1.87; 95% CI, 0.77-4.53; Figure 3C). Expression of MYC alone or in 
combination with BCL2 (DE) had no adverse effect on survival (data not shown). 
The two PCDLBCL-LT patients with a double hit had a favorable disease course. Notably, in 
both patients disease was located on the abdomen and not on the legs (Figure 2). Both patients 
were initially treated with radiotherapy with complete regression of the lesions. One patient 
remained disease-free and died after 86 months from an unrelated cause, while the other double hit 
patient developed positive inguinal lymph nodes after 17 months of follow-up, but reached 
complete remission after R-CHOP treatment (8x) with a total follow-up duration of 40 months. 
 
DISCUSSION 
In the present study, we investigated the frequency and prognostic significance of MYC 
rearrangements with or without a double hit in BCL2 and/or BCL6 and of DE in 44 patients with 
PCDLBCL-LT and 17 patients with PCFCL.  
A subset of 32% of the PCDLBCL-LT patients had a rearrangement of the MYC gene, with a 
double hit in BCL6 in 2 of these patients, while all PCFCL cases were MYC-wild type. The percentage 
of MYC rearrangements in PCDLBCL-LT falls within the wide range of the previously reported studies 
with small patient numbers (0% to 43%).(22, 24-26) Our frequency, however, is higher than reported 
in nodal DLBCL (9 to 14%) (5-8) and other extranodal DLBCL, such as DLBCL of the central nervous 
system (CNS-DLBCL) (up to 9%) (28-30). Similar to nodal DLBCL in which MYC rearrangements are 
associated with a poor outcome, PCDLBCL-LT patients with a MYC rearrangement had a statistically 
significant inferior 5-year DSS and DFS compared with PCDLBCL-LT patients without a MYC 
rearrangement (Figure 3). 
To the best of our knowledge, this is the first study that reports the presence of double hits 
in PCDLBCL-LT patients. In our cohort, 2 of the MYC-rearranged patients had a double hit in BCL6. A 
double hit with BCL6 instead of BCL2 is in line with expectations, as in nodal DLBCL with an ABC 
phenotype, double hits with BCL2 do not occur.(17) Similarly, in CNS-DLBCL, that also has an ABC 
phenotype, a case report describes a patient with a double hit involving BCL6 and not BCL2.(29) 
Notably, the disease course of the PCDLBCL-LT patients with a double hit seemed favorable 
compared with the patients with a single or no MYC rearrangement, but the number is too small to 
8 
 
draw any conclusions. This finding, however, is in line with the presence of a double hit in BCL6 
instead of BCL2, as in nodal DLBCL, the association with poor outcome especially accounts for cases 
with a double hit in BCL2 or triple hits, and less for patients with a double hit in BCL6.(6, 7, 31) 
Despite the GCB-phenotype of PCFCL, no MYC hits, nor double hits, were present in our group of 
PCFCL patients. This is in line with previous studies(24, 32), except for one study that reported DE in 
6/21 (29%) cases of PCFCL including one case with a double hit in MYC and BCL6.(26) 
In contrast to reported studies in nodal DLBCL (14, 15) and CNS-DLBCL (33-35), DE was not 
associated with an inferior survival in our cohort of patients with PCDLBCL-LT. Few studies with a 
limited number of patients evaluated the prognostic significance of DE in CBCL, showing an inferior 
survival for the group as a whole -as can be expected by the differences in immune profile and 
prognosis of PCDLBCL-LT and PCFCL patients-, but with contradicting results for only the PCDLBCL-LT 
patients.(26, 32) As almost all cases of PCDLBCL-LT expressed BCL2, which is a known characteristic 
of this disease(19, 20), the percentage of DE (65%) was similar to MYC expression alone (67%). The 
percentage of DE in our cohort of PCDLBCL-LT patients corresponds with previously reported 
percentages of 55 to 83%.(22, 26, 32) In addition, MYC protein expression was not suitable for the 
prediction of a MYC rearrangement with especially a low positive predictive value of 41%. Some 
studies suggest that a cutoff value of 70% for MYC has the highest predictive value(36), however, 
this was not confirmed in our study with only a slight improvement of the positive predictive value 
to 56%. 
On the basis of our results with high frequency and prognostic significance of MYC 
rearrangements in PCDLBCL-LT but not PCFCL, we suggest that it may be useful to perform MYC-FISH 
in all newly diagnosed PCDLBCL-LT patients, as is currently also standard practice in newly diagnosed 
nodal DLBCL patients.(27) Because of the rarity of double hits in our cohort, the absence in previous 
studies(22, 24), and the combination of a double hit with BCL6 instead of BCL2, additional FISH for 
BCL2 and BCL6 in case of a MYC rearrangement seems to have no clinical relevance in patients with 
PCDLBCL-LT. Immunostaining for MYC protein may be used as an adjunctive marker to differentiate 
between PCDLBCL-LT and PCFCL with a diffuse large cell morphology in equivocal cases, but is not 
useful as a prognostic marker, nor as a predictive marker for a MYC rearrangement. 
This study demonstrates that MYC-rearranged PCDLBCL-LT patients may need more 
intensive disease monitoring during follow-up due to the higher risk for disease-progression and 
death from lymphoma. Also, the presence of a MYC rearrangement in PCDLBCL-LT patients may be 
interesting with regard to therapeutic strategies, such as intensifying chemotherapeutic regimens 
using dose-adjusted EPOCH-R instead of R-CHOP, which is also well tolerated in patients older than 
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60 years.(37) Moreover, in the future possible new therapies may be developed targeting the MYC 
pathway with restoration of the immune response.(38) 
In conclusion, this study identifies a high incidence of MYC rearrangements in PCDLBCL-LT 
but not PCFCL and suggests that PCDLBCL-LT patients with a MYC rearrangement have a higher risk 
for disease-progression and death from lymphoma. Therefore, it may be useful to perform MYC-FISH 
in all newly diagnosed PCDLBCL-LT patients. 
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FIGURE LEGENDS 
FIGURE 1. Overview of results of FISH for MYC, BCL2, and BCL6 and immunohistochemistry for 
MYC and BCL2 in 44 patients with PCDLBCL-LT. OncoPrinter plot showing a MYC rearrangement in 
32% of the patients with a double hit in BCL6 in 4%, and no double hits in BCL2. Protein expression of 
MYC was present in 67% and BCL2 in 95% with double expression of MYC and BCL2 in 65% of the 
patients. 
 
FIGURE 2. Clinical presentation, histology, and FISH of a patient with PCDLBCL-LT with a double hit 
in MYC and BCL6. The skin of the lower abdomen shows brown to reddish, infiltrated tumors (A). 
The skin biopsy (HE 1 [B], HE 2 [C]) contains diffuse dermal sheets of large, blastic cells with 
prominent nucleoli, and mitotic figures with infiltration of the subcutaneous tissue and sparing of 
the epidermis. The tumor cells are positive for CD20 (D), MUM1 (F), IgM (G), BCL2 (I), and MYC (H), 
but negative for CD10 (E) and BCL6 (J). Stainings: HE 1, HE 2, and immunohistochemical. FISH shows 
rearrangements of MYC (K) and BCL6 (M), and no rearrangement of BCL2 (L). 
 
FIGURE 3. Survival analysis for MYC status in 44 patients with PCDLBCL-LT. Kaplan-Meier survival 
curves show a statistically significant adverse effect on (A) DSS (Log-rank, p=0.036; HR, 2.67; 95% CI, 
1.03-6.96), and (B) DFS (Log-rank, p=0.028; HR, 2.47; 95% CI, 1.05-5.78), but not on (C) OS of the 
patients (Log-rank, p=0.157; HR, 1.87; 95% CI, 0.77-4.53) at 5 years. Survival was defined as the date 
of diagnosis until the date of death by any cause (OS) or the date of death from lymphoma (DSS). 
DFS was calculated from the date of diagnosis until the time of progression or relapse of disease or 
death from lymphoma. Patients without an event at the last date of follow-up were censored. 
Table 1. Patient characteristics and overview of results of 44 patients with primary cutaneous 
diffuse large B-cell lymphoma, leg type 
Characteristic Total 
(n=44) 
MYC status  
 
p-value* 
Double expressiona  
 
p-value** 
rearranged 
(n=14) 
wild type 
(n=30) 
present 
(n=28) 
absent 
(n=15) 
Gender, n (%) 
- female 
- male 
 
25 (57) 
19 (43) 
 
8 (57) 
6 (43) 
 
17 (57) 
13 (43) 
.976  
16 (57) 
12 (43) 
 
8 (53) 
7 (47) 
.811 
Age at diagnosis in years, median (range) 78 (49-92) 78.5 (49-86) 78 (53-92) .622 78.5 (49-90) 78 (53-92) .540 
Disease localisation, n (%) 
- legs 
- other sites 
 
35 (80) 
9 (20) 
 
10 (71) 
4 (29) 
 
25 (83) 
5 (17) 
.362  
23 (82) 
5 (18) 
 
11 (73) 
4 (27) 
.499 
Extent of disease, n (%) 
- solitary 
- localized 
- generalized 
 
11 (25) 
28 (64) 
5 (11) 
 
2 (14) 
9 (64) 
3 (21) 
 
9 (30) 
19 (63) 
2 (7) 
.250  
6 (21) 
17 (61) 
5 (18) 
 
4 (27) 
11 (73) 
- 
.220 
Initial therapy, n (%) 
- local therapyb 
- immunochemotherapy (R-CHOP)c 
- chemotherapy (CHOP)c 
- no treatmentd 
 
21 (48) 
16 (36) 
6 (14) 
1 (2) 
 
3 (21) 
6 (43) 
4 (29) 
1 (7) 
 
18 (60) 
10 (33) 
2 (7) 
- 
.035  
11 (39) 
10 (36) 
6 (21) 
1 (4) 
 
9 (60) 
6 (40) 
- 
- 
  .128 
Status at last follow-up, n (%) 
- alive w/o disease 
- alive w/ disease 
- died of lymphoma 
- died unrelated 
 
11 (25) 
4 (9) 
20 (45) 
9 (20) 
 
1 (7) 
2 (14) 
9 (64) 
2 (14) 
 
10 (33) 
2 (7) 
11 (37) 
7 (23) 
.157  
5 (18) 
3 (11) 
13 (46) 
7 (25) 
 
6 (40) 
1 (7) 
7 (47) 
1 (7) 
.283 
5-year overall survival, % 46 30 52 .157 44 53 .718 
5-year disease-specific survival, % 52 30 62 .036 51 53 .898 
5-year disease-free survival, % 44 25 53 .028 41 49 .815 
Immunophenotype, n (%) 
- MYCa 
- CD10 
- BCL6 
- MUM1a 
- BCL2  
- IgM 
 
29 (67) 
7 (16) 
27 (61) 
36 (84) 
42 (95) 
42 (95) 
 
12 (86) 
0 (0) 
6 (43) 
10 (71) 
14 (100) 
13 (93) 
 
17 (59) 
7 (23) 
21 (70) 
26 (90) 
28 (93) 
29 (97) 
 
.086 
.049 
.085 
.129 
.323 
.572 
 
28 (100) 
6 (21) 
18 (64) 
23 (82) 
28 (100) 
27 (96) 
 
1(7) 
1 (7) 
8 (53) 
13 (87) 
13 (87) 
14 (93) 
 
NA 
.211 
.484 
.702 
NA 
.646 
MYC status, n (%) 
- rearrangement 
- wild type 
 
14 (32) 
30 (68) 
 
NA 
 
NA 
NA  
12 (43) 
16 (57) 
 
2 (13) 
13 (87) 
.049 
Double hite 2 (4) 2 (14) NA NA 1 (4) 1 (7) .646 
Abbreviations: R-CHOP, rituximab with cyclophosphamide, doxorubicin, vincristine, and prednisone; CHOP, 
cyclophosphamide, doxorubicin, vincristine, and prednisone; NA, not applicable. 
aData is missing in one case. 
bLocal therapy consisted of radiotherapy alone in 19 patients, radiotherapy with surgical excision in one patient, and 
surgical excision alone in one patient. 
c(Immuno)chemotherapy was combined with radiotherapy in nine patients. 
dNo treatment was given due to spontaneous remission of the solitary lesion. 
eDouble hits occurred only in combination with BCL6, not with BCL2. 
*Comparison between MYC-rearranged and MYC-wild type patients. 
**Comparison between patients with and without double expression of MYC and BCL2. 



